App-Quantinova.ai

Trends in ADAMTS13 Activity Testing over the Last 7 Years in a Single UK TTP Specialist Centre

Kat Moss - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Tackling Cancer Associated Thrombosis: A Multi-Professional Approach

Sumantha Gabriel - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Tinzaparin

Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada

Jonathan Belsey - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic veno-occlusive disease with immunodeficiency

Defibrotide

Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis

Robert F. Sidonio - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

rFVIIa

How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations

Benjamin Djulbegovic - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Lani Lieberman - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Methadone hydrochloride

The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)

Georg Lenz - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

Emmanuel Bachy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Cyclophosphamide

Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands

Carin A. Uyl-de Groot - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

Estimating Long-Term Survival in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients

Stephen Palmer - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Philip L. McCarthy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis

Karthik Ramasamy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study

Anthony R Mato - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Idelalisib

Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

John Ashcroft - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Sparsentan

Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISh)

Caroline Kruse - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Risk-Benefit and Cost-Effectiveness of Universal Iron Interventions for Public Health Control of Anemia in Young Children in 78 Countries: A Microsimulation Study

Sant-Rayn Pasricha - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Malaria

N/A

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Validation of Sickle Cell Disease Severity Score in a Cohort of Hemoglobin SC Disease Patients

Rebecca Marie Rosart - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Results from the ITP World IMPACT Survey (I-WISh): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives

Nichola Cooper - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Filters

45280 Abstracts